Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2006New England Journal of MedicineOpen Access

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

View Full Paper
Ask AI
Bookmark
Share

Authors

Moshe TalpazMoshe TalpazUniversity of VeronaNSNeil P. ShahReckitt Benckiser (United Kingdom)Hagop M. KantarjianHagop M. KantarjianThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Talpaz et al. (2006) studied this question.

synapsesocial.com/papers/69da28eb387cf70698686625https://doi.org/10.1056/nejmoa055229
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.2004 · 79 citations
  2. 2Sustained Durability of Responses Plus High Rates of Cytogenetic Responses Result in Long-Term Benefit for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Treated with Imatinib (IM) Therapy: Update from the IRIS Study.2004 · 51 citations
  3. 3The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor.2004 · 25 citations
  4. 4Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL2006 · 1,350 citations
  5. 5High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance2002 · 659 citations